Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines

Christopher D. Coldren, Barbara A. Helfrich, Samir E. Witta, Michio Sugita, Razvan Lapadat, Chan Zeng, Anna Barón, Wilbur A. Franklin, Fred R. Hirsch, Mark W. Geraci, Paul A. Bunn

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechanism of primary resistance is unclear. We used microarray gene expression profiling to uncover a pattern of gene expression associated with sensitivity to EGFR-TKIs by comparing NSCLC cell lines that were either highly sensitive or highly resistant to gefitinib. This sensitivity-associated expression profile was used to predict gefitinib sensitivity in a panel of NSCLC cell lines with known gene expression profiles but unknown gefitinib sensitivity. Gefitinib sensitivity was then determined for members of this test panel, and the microarray-based sensitivity prediction was correct in eight of nine NSCLC cell lines. Gene and protein expression differences were confirmed with a combination of quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry. This gene expression pattern related to gefitinib sensitivity was independent from sensitivity associated with EGFR mutations. Several genes associated with sensitivity encode proteins involved in HER pathway signaling or pathways that Interrelate to the HER signaling pathway. Some of these genes could be targets of pharmacologic interventions to overcome primary resistance.

Original languageEnglish (US)
Pages (from-to)521-528
Number of pages8
JournalMolecular Cancer Research
Volume4
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Gene Expression
Cell Line
Protein-Tyrosine Kinases
Proteins
Gene Expression Profiling
Transcriptome
Genes
Reverse Transcription
Flow Cytometry
Immunohistochemistry
gefitinib
Polymerase Chain Reaction
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Coldren, C. D., Helfrich, B. A., Witta, S. E., Sugita, M., Lapadat, R., Zeng, C., ... Bunn, P. A. (2006). Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Molecular Cancer Research, 4(8), 521-528. https://doi.org/10.1158/1541-7786.MCR-06-0095

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. / Coldren, Christopher D.; Helfrich, Barbara A.; Witta, Samir E.; Sugita, Michio; Lapadat, Razvan; Zeng, Chan; Barón, Anna; Franklin, Wilbur A.; Hirsch, Fred R.; Geraci, Mark W.; Bunn, Paul A.

In: Molecular Cancer Research, Vol. 4, No. 8, 08.2006, p. 521-528.

Research output: Contribution to journalArticle

Coldren, CD, Helfrich, BA, Witta, SE, Sugita, M, Lapadat, R, Zeng, C, Barón, A, Franklin, WA, Hirsch, FR, Geraci, MW & Bunn, PA 2006, 'Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines', Molecular Cancer Research, vol. 4, no. 8, pp. 521-528. https://doi.org/10.1158/1541-7786.MCR-06-0095
Coldren, Christopher D. ; Helfrich, Barbara A. ; Witta, Samir E. ; Sugita, Michio ; Lapadat, Razvan ; Zeng, Chan ; Barón, Anna ; Franklin, Wilbur A. ; Hirsch, Fred R. ; Geraci, Mark W. ; Bunn, Paul A. / Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. In: Molecular Cancer Research. 2006 ; Vol. 4, No. 8. pp. 521-528.
@article{3add5c77eb874854ae0b08c183848503,
title = "Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines",
abstract = "Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechanism of primary resistance is unclear. We used microarray gene expression profiling to uncover a pattern of gene expression associated with sensitivity to EGFR-TKIs by comparing NSCLC cell lines that were either highly sensitive or highly resistant to gefitinib. This sensitivity-associated expression profile was used to predict gefitinib sensitivity in a panel of NSCLC cell lines with known gene expression profiles but unknown gefitinib sensitivity. Gefitinib sensitivity was then determined for members of this test panel, and the microarray-based sensitivity prediction was correct in eight of nine NSCLC cell lines. Gene and protein expression differences were confirmed with a combination of quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry. This gene expression pattern related to gefitinib sensitivity was independent from sensitivity associated with EGFR mutations. Several genes associated with sensitivity encode proteins involved in HER pathway signaling or pathways that Interrelate to the HER signaling pathway. Some of these genes could be targets of pharmacologic interventions to overcome primary resistance.",
author = "Coldren, {Christopher D.} and Helfrich, {Barbara A.} and Witta, {Samir E.} and Michio Sugita and Razvan Lapadat and Chan Zeng and Anna Bar{\'o}n and Franklin, {Wilbur A.} and Hirsch, {Fred R.} and Geraci, {Mark W.} and Bunn, {Paul A.}",
year = "2006",
month = "8",
doi = "10.1158/1541-7786.MCR-06-0095",
language = "English (US)",
volume = "4",
pages = "521--528",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines

AU - Coldren, Christopher D.

AU - Helfrich, Barbara A.

AU - Witta, Samir E.

AU - Sugita, Michio

AU - Lapadat, Razvan

AU - Zeng, Chan

AU - Barón, Anna

AU - Franklin, Wilbur A.

AU - Hirsch, Fred R.

AU - Geraci, Mark W.

AU - Bunn, Paul A.

PY - 2006/8

Y1 - 2006/8

N2 - Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechanism of primary resistance is unclear. We used microarray gene expression profiling to uncover a pattern of gene expression associated with sensitivity to EGFR-TKIs by comparing NSCLC cell lines that were either highly sensitive or highly resistant to gefitinib. This sensitivity-associated expression profile was used to predict gefitinib sensitivity in a panel of NSCLC cell lines with known gene expression profiles but unknown gefitinib sensitivity. Gefitinib sensitivity was then determined for members of this test panel, and the microarray-based sensitivity prediction was correct in eight of nine NSCLC cell lines. Gene and protein expression differences were confirmed with a combination of quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry. This gene expression pattern related to gefitinib sensitivity was independent from sensitivity associated with EGFR mutations. Several genes associated with sensitivity encode proteins involved in HER pathway signaling or pathways that Interrelate to the HER signaling pathway. Some of these genes could be targets of pharmacologic interventions to overcome primary resistance.

AB - Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechanism of primary resistance is unclear. We used microarray gene expression profiling to uncover a pattern of gene expression associated with sensitivity to EGFR-TKIs by comparing NSCLC cell lines that were either highly sensitive or highly resistant to gefitinib. This sensitivity-associated expression profile was used to predict gefitinib sensitivity in a panel of NSCLC cell lines with known gene expression profiles but unknown gefitinib sensitivity. Gefitinib sensitivity was then determined for members of this test panel, and the microarray-based sensitivity prediction was correct in eight of nine NSCLC cell lines. Gene and protein expression differences were confirmed with a combination of quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry. This gene expression pattern related to gefitinib sensitivity was independent from sensitivity associated with EGFR mutations. Several genes associated with sensitivity encode proteins involved in HER pathway signaling or pathways that Interrelate to the HER signaling pathway. Some of these genes could be targets of pharmacologic interventions to overcome primary resistance.

UR - http://www.scopus.com/inward/record.url?scp=33748425912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748425912&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-06-0095

DO - 10.1158/1541-7786.MCR-06-0095

M3 - Article

VL - 4

SP - 521

EP - 528

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 8

ER -